Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Guardant Health Inc. (GH)

NASDAQ: GH · Services-Medical Laboratories · Palo Alto, CA

Our rating: Positive

Call changed from Cautious to Positive at $150.87, moderate conviction, November 6, 2026.

Breaks if: The Positive call breaks if Guardant reports revenue growth below 20% year-over-year in two consecutive quarterly filings — that would signal Shield adoption has plateaued and the core oncology monitoring business cannot compensate, removing the rationale for a premium multiple. The call also breaks if the annual free cash flow deficit widens beyond $350M over the next four quarters, indicating that spending is outrunning the revenue ramp and pushing the already-invisible profit horizon further out of reach.

Key figures

Market value$19.7B
Revenue, last 12 months$1.3B
Net income, last 12 months−$485M
Free cash flow, last 12 months−$232M
Price to earningsn/a
Free cash flow yield−1.2%
Dividend yield0.0%
Operating margin−39.4%
Return on equityn/a
Beta to the S&P 5001.18
Volatility, annualized61.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$361M36.1%$-0.93−$37M
June 30, 2026$335M44.3%$-0.90−$70M
March 31, 2026$302M48.3%$-0.85−$71M
December 31, 2025$281M39.4%$-1.00−$54M
September 30, 2025$265M38.5%$-0.74−$46M
June 30, 2025$232M30.9%$-0.80−$66M
March 31, 2025$203M20.8%$-0.77−$67M
December 31, 2024$202M30.2%$-0.90−$83M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.